Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 6/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.37 |
| ▸ | TYR | P14679 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17676536 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL13470053 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL13469658 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL13454443 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL13469661 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL24218349 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL17676530 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL13454441 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL17676531 | 1.00 | SLC5A2 (0.37) | SLC5A2SLC5A1TYRATM | |
| SCHEMBL13470054 | 0.95 | TYR (0.40) | SLC5A2SLC5A1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9308185-B2 | Glyco-substituted dihydroxy-chlorins and β-functionalized chlorins for anti-microbial photodynamic therapy | BIOLITEC PHARMA MARKETING LTD (MY) | 2016-04-12 | — | — | US | disclosed |
| US-20120263625-A1 | GLYCO-SUBSTITUTED DIHYDROXY-CHLORINS AND ß-FUNCTIONALIZED CHLORINS FOR ANTI-MICROBIAL PHOTODYNAMIC THERAPY | CERAMOPTEC INDUSTRIES, INC. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263625-A1 | GLYCO-SUBSTITUTED DIHYDROXY-CHLORINS AND ß-FUNCTIONALIZED CHLORINS FOR ANTI-MICROBIAL PHOTODYNAMIC THERAPY | DDT, CD2, HBG1 | SLC5A2 832/4885SLC5A1 873/4885TYR 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.